Review Article

Merkel cell polyomavirus and non-Merkel cell carcinomas: guilty or circumstantial evidence?*

BALINT CSOBOZ, KASHIF RASHEED, BALDUR SVEINBJØRNSSON and UGO MOENS

Molecular Inflammation Research Group, Department of Medical Biology, University of Tromsø – The Arctic University of Norway, Tromsø, Norway

Merkel cell polyomavirus (MCPyV) is the major causative factor of the rare but aggressive cancer, Merkel cell carcinoma (MCC). Two characteristics of MCPyV-positive MCCs are integration of the viral genome and expression of a truncated version of one of its oncogenic proteins, namely large T antigen. The strong association of MCPyV with MCC development has incited researchers to further investigate a possible role of this virus in other cancers. However, many of the examples displaying the presence of the virus in the various non-MCC cancers are not able to clearly demonstrate a direct connection between cellular transformation and the presence of the virus. The prevalence of the virus is significantly lower in non-MCC cancers compared to MCCs, with a lower level of viral load and sparse viral protein expression. Moreover, the state of the viral genome, and whether a truncated large T antigen is expressed, has rarely been investigated. Nonetheless, considering the strong oncogenic potential of MCPyV proteins in MCC, the plausible contribution of MCPyV to transformation and cancer growth in non-MCC tumors cannot be ruled out. Furthermore, the absence of MCPyV in cancers does not exclude a hit-and-run mechanism, or the oncoproteins of MCPyV may potentiate the neoplastic process mediated by co-infecting oncoviruses such as high-risk human papillomaviruses and Epstein-Barr virus. The current review is focusing on the available data describing the presence of MCPyV in non-MCC tumors, with an aim to provide a comprehensive overview of the corresponding literature and to discuss the potential contribution of MCPyV to non-MCC cancer in light of this.

Key words: Merkel cell polyomavirus; Merkel cell carcinoma; non-Merkel cell carcinomas; viral carcinogenesis; viral oncoprotein; oncogenic DNA viruses.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
natural host. Raccoon polyomavirus is associated with brain tumors in raccoons (12), while the human polyomavirus Merkel cell polyomavirus (MCPyV) is strongly correlated with the rare skin tumor Merkel cell carcinoma (MCC) (13–16). MCPyV was originally identified in 2008 by the group of Cheng and Moore (13), who showed that the viral genome was integrated into the host genome, interrupting the late region. In addition, a C-terminal truncated LT was also expressed. This deletion removed the helicase activity of LT, which is required for viral DNA replication. Worldwide studies by many groups have now shown that approximately 80% of all MCCs are positive for MCPyV and that the viral genome is integrated, and a C-terminal truncated LT is expressed (14). Virus-positive tumors usually contain >1 genome copies per cell (17–21). MCC is considered as a rare but aggressive type of skin cancer, being among the fastest growing tumors with a mortality rate of ~45% (14). The incidence has increased significantly during the last 10 years and is prospected to increase further, as its occurrence is associated with aging and exposure to the sun (22). It is generally accepted that MCPyV is a major cause of MCC (14). During the transformation process, the virus is monoclono-
ally integrated into the genome of the tumor cells, thereby indicating that the proto-tumor cell was infected with the virus prior to its cancerous expansion (13). Furthermore, the oncogenic LT of the virus is expressed in all of the tumor cells, and when it is inhibited, MCPyV-positive cells die (23).

Seroepidemiological studies revealed that MCPyV infects most humans and establishes a life-long harmless persistent infection in healthy individuals (24–26). Antibodies against viral proteins are detected in 50%–80% of the serum from healthy adults and children (27, 28). Moreover, MCPyV is chronically shed from the skin of healthy individuals (29), thereby indicating that MCPyV is a part of the human skin microbiome. The natural host cell for MCPyV replication in the human body could be dermal fibroblasts cells, as virus could be propagated in human dermal fibroblast cell cultures (30). The replicated viral genome was measured in an extremely high copy number at approximately 12 000 copies per cell in cell cultures (30), in contrast to MCC samples in which the MCPyV genome was assessed to be present at an average copy number of 5.2 (range 0.8–14.3) per cell (21). MCPyV was also shown to be capable of expressing LT and VP1 in fibroblast cell lines originating from lung tissue (30). Hence, an active viral replication of MCPyV might be connected to fibroblast tissues in general. Besides the fact that dermal fibroblasts are primarily residing in the dermis layer of the skin, cutaneous swabs were also shown to contain MCPyV DNA (31). This suggests that viral particles can be more widespread from the site of replication and release. A study using a wide cohort of patients has also described an age-related increase in the prevalence of MCPyV DNA in the sun-exposed skin of patients (32), thus suggesting an age-related association of viral replication in the host. Increased viral activity may result from a weakened immune survey (immune senes-
cence or immunosuppression), which is supported by the fact that a higher occurrence of MCC was observed in organ transplant patients undergoing immunosuppressive treatments (33), as well as in patients with severe T-cell leukemia (34).

**MCPyV in Non-Cancerous Tissues**

Despite the fact that the replication of MCPyV has so far shown to be limited to fibroblasts from the dermis and potentially from the lung (30), MCPyV DNA has been detected in various non-cancerous tissues of the body like the adrenal gland, spleen, bone marrow, stomach, gallbladder, pancreas, heart, and aorta, although with a relatively low viral load between 0.00026 and 0.22 copies per cell (35). On average, the viral genome copy number of MCPyV was 60 times lower in healthy tissues across the body compared to MCC samples (36). A study identified the highest presence for MCPyV among different tissues in the digestive system, saliva, and in the upper aerodigestive tract (36). MCPyV DNA was also present in bodily fluids, such as the blood and urine from two patients with advanced MCC (one with immunosuppression and one without immunosuppressive side treatments). However, viral DNA was not detected in the whole blood samples of patients without MCC by using simple PCR (37). MCPyV positivity in blood was associated with monocytes, and MCPyV was shown to be selectively associated with the CD14+CD16− ‘inflammatory’ monocyte subpopulation. This finding suggests that inflammation-associated monocytes might serve as potential vehicles for MCPyV, which could aid viral transmission in the body through harboring and transferring the virus to inflammation sites (37). In contrast, MCPyV DNA sequences were amplified in the buffy coats of blood, with a very low viral load of 10 to 100 molecules/100 000 cells (38). The reason that the low levels of MCPyV DNA were identified in this study might have originated from the fact that the blood samples were prefractionated by a density gradient centrifugation in order to obtain the leukocyte rich fraction. Subsequently, circulating MCPyV DNA was detected in the unfractionated sera of healthy individuals by using a more sensitive quantitative
| Tissue (n) | Prevalence (average%; range) | Viral load | Method | Comments | Reference |
|-----------|-----------------------------|------------|--------|----------|-----------|
| Lymphatic system | | | | | |
| Tonsillar SCC (150) | 48 (32.0; 21.1–35.7) | 0.000064–0.00038 | qPCR (LT, sT) | | (41, 77, 78) |
| Chronic tonsillitis and tonsillar hyperplasia (497) | 21 (4.2; 0.0–54.7) | 0.00004–0.00018 | qPCR (LT) | | (78, 143–145) |
| Hypertrophy adenoid (179) | 3 (1.7; 1.3%–10%) | 0.00036 | qPCR (LT), FISH (LT), IHC (LT) | 6/7 were also positive by ISH and 3/7 were positive by IHC. | (145) |
| Thymoma (46) | 7 (15.2; 0–19.4) | | qPCR (LT, sT), FISH (LT), IHC (LT) | | (69, 79, 80) |
| Carcinoid of the thymus (5) | 0 (0) | qPCR (LT) | | | (146) |
| Normal healthy lymph nodes (2) | 0 (0) | IHC (LT) | | | (17) |
| Nervous system | | | | | |
| Brain tumors (176) | 3 (1.7; 0–30) | 0.0000007–0.05051 | qPCR (LT, sT, VP1), nPCR (LT), IHC (LT) | | (62, 75, 98, 118, 146, 147) |
| Glioblastoma (46) | 2 (4.3; 0–28.6) | <0.0001 | qPCR (LT) | | (115, 148) |
| Meningioma (12) | 8 (66.7) | 0.000 | qPCR (LT), IHC (LT) | | (115) |
| Neuroblastoma (57) | 0 (0) | | qPCR (LT, VP1) | | (65, 105) |
| Neurofibroma (1) | 0 (0) | | qPCR (LT) | | (80) |
| Schwannoma (19) | 12 (63.2; 0–78.6) | | | One schwannoma sample had LT transcripts. | (80, 100, 115) |
| Skeletal system | | | | | |
| Bone from patients with Langerhans cell histiocytosis (5) | 4 (80) | 0.002–0.027 | qPCR (LT) | | (149) |
| Chondrosarcoma (25) | 0 (0) | RT-PCR (LT, VP1) | | | (114) |
| Chordoma (18) | 0 (0) | RT-PCR (LT, VP1) | | | (114) |
| Ewing sarcoma (37) | 1 (2.7; 0–14.3) | qPCR (LT); PCR (LT, VP1) | | | (65, 105) |
| Rhabd oblasmocellular carcinoma (7) | 0 (0) | qPCR (LT) | | | (105) |
| Small-cell cancer of the bone (2) | 0 (0) | IHC (LT) | | | (98) |
| Endocrine system | | | | | |
| Neuroendocrine carcinoma (102) | 3 (2.9; 0–5) | PCR (LT), qPCR (LT, sT), IHC (LT) | | | (62, 119, 150, 151) |
| Neuroendocrine tumor of the gastrointestinal tract (1) | 0 (0) | IHC (LT) | | | (17) |
| Excretory system | | | | | |
| Bladder cancer (149) | 6 (4.0; 0–75) | 0.004 | qPCR (LT, VP1), IHC (LT) | | (36, 62, 65, 98) |
| Renal cancer (81) | 3 (3.7; 0–18.9) | 0.001 | qPCR (LT, VP1), IHC (LT) | | (36, 62) |
| Respiratory system | | | | | |
| Bronchial carcinoid (11) | 0 (0) | PCR (LT) | | | (146) |
| Large-cell carcinoma (32) | 1 (33.3) | PCR (LT); PCR (LT, VP1), qPCR (LT) | | | (69) |
| Extrapulmonary small-cell carcinoma (16) | 3 (18.8) | qPCR (LT, sT) | | | (152) |
| Lung cancer (388) | 12 (3.1; 0–35.7) | 0.001 | qPCR (LT, VP1), nPCR (VP1), IHC (LT) | | (36, 60–62, 65, 153) |
| Mesothelioma (138) | 1 (0.7; 0–4.2) | <0.00015 | qPCR (LT, sT), IHC (LT) | | (62, 69, 154) |
| Neuroendocrine cancer of the lung (37) | 0 (0) | PCR (LT), IHC (LT) | | | (57, 146, 155) |
| NSCLC (910) | 148 (16.3; 0–100) | PCR (LT, sT), qPCR (LT, VP1), RT-PCR (LT, VP1) | Integrated viral DNA in one adenosarcoma sample with expression of truncated LT. Integrated + episomal viral DNA in one | | (67, 69–72, 76, 156–161) |
| Tissue (n)                                      | Prevalence (average%; range) | Viral load \(^1\) | Method                                                                 | Comments                                                                 | Reference |
|------------------------------------------------|-----------------------------|-------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------|
| SCC sample with expression of full-length and truncated LT. |                             | 0.0008            | PCR (LT, VP1), qPCR (sT)                                              | SCC sample with expression of full-length and truncated LT.              | (69)      |
| SCLC (193)                                      |                             | 0.000805-0.026    | PCR (LT, VP1), qPCR (LT, VP2), PCR (LT)/Southern blot2, qPCR (LT, VP1), IHC (LT) | Two different LT antibodies were used.                                    | (17, 63, 64, 66-68, 98, 146, 155, 162) |
| Digestive tract                                |                             |                   |                                                                        |                                                                          |           |
| Oral cavity (including lip, cheek, tongue, throat, larynx, jaw) (531) |                             | 0.00024-0.026     | PCR (LT, sT, VP1), qPCR (LT, sT, VP1), IHC (LT) | One positive parotid sample expressed truncated LT.                     | (36, 60, 98, 100, 110, 141, 163, 164) |
| Salivary gland cancer (185)                    |                             |                   |                                                                        |                                                                          |           |
| Esophagus cancer (156)                         |                             | 0.000054-0.000024 | qPCR (LT, VP1), PCR (LT, VP1), IHC (LT) | HIV-positive men.                                                        |           |
| Stomach cancer (58)                            |                             | 0.000054-0.00024  | qPCR (LT, VP1), PCR (LT, VP1), IHC (LT)                              |                                                                          | (36, 106, 109) |
| Liver cancer (27)                              |                             | 0.000054-0.00024  | qPCR (LT, VP1), PCR (LT, VP1), IHC (LT)                              |                                                                          | (57, 62, 65) |
| Gallbladder cancer (1)                         |                             | 0.000054-0.00024  | qPCR (LT, VP1), PCR (LT, VP1), IHC (LT)                              |                                                                          |           |
| Intestine cancer (11)                          |                             | 0.000054-0.00024  | qPCR (LT, VP1), PCR (LT, VP1), IHC (LT)                              |                                                                          |           |
| Colorectal cancer (340)                        |                             | 0.000054-0.00024  | qPCR (LT, VP1), PCR (LT, VP1), IHC (LT)                              |                                                                          |           |
| Appendix (4)                                   |                             | 0.000054-0.00024  | qPCR (LT, VP1), PCR (LT, VP1), IHC (LT)                              |                                                                          |           |
| Gastrointestinal cancers (8)                   |                             | 0.000054-0.00024  | qPCR (LT, VP1), PCR (LT, VP1), IHC (LT)                              |                                                                          |           |
| Reproductive system                            |                             |                   |                                                                        |                                                                          |           |
| Prostate cancer (64)                           |                             | 0.000054-0.00024  | qPCR (LT, VP1), qRT-PCR (LT), NGS, IHC (LT)                          | Some samples also positive for LT transcripts and protein 140 of the examined women were HIV-positive. | (65, 98, 103, 155, 168); |
| Testicular cancer (9)                          |                             | 0.000054-0.00024  | qPCR (LT, VP1), qRT-PCR (LT), NGS, IHC (LT)                          | Some samples also positive for LT transcripts and protein 140 of the examined women were HIV-positive. | (36, 98, 103, 167) |
| Penile intraepithelial neoplasia and acanthoma/benign papilloma (20) |                             | 0.000054-0.00024  | qPCR (LT, VP1), qRT-PCR (LT), NGS, IHC (LT)                          | Some samples also positive for LT transcripts and protein 140 of the examined women were HIV-positive. | (36, 98, 103, 167) |
| Cervical cancer (328)                          |                             | 0.000054-0.00024  | qPCR (LT, VP1), qRT-PCR (LT), NGS, IHC (LT)                          | Some samples also positive for LT transcripts and protein 140 of the examined women were HIV-positive. | (36, 98, 103, 155, 168); |
| Uterine cancer (4)                             |                             | 0.000054-0.00024  | qPCR (LT, VP1), qRT-PCR (LT), NGS, IHC (LT)                          | Some samples also positive for LT transcripts and protein 140 of the examined women were HIV-positive. | (65, 98, 103, 155, 168); |
| Ovarian cancer (186)                           |                             | 0.000054-0.00024  | qPCR (LT, VP1), qRT-PCR (LT), NGS, IHC (LT)                          | Some samples also positive for LT transcripts and protein 140 of the examined women were HIV-positive. | (65, 98, 103, 155, 168); |
| Cancer of the vulva (2)                        |                             | 0.000054-0.00024  | qPCR (LT, VP1), qRT-PCR (LT), NGS, IHC (LT)                          | Some samples also positive for LT transcripts and protein 140 of the examined women were HIV-positive. | (65, 98, 103, 155, 168); |
| Breast cancer (474)                            |                             | 0.000054-0.00024  | qPCR (LT, VP1), qRT-PCR (LT), NGS, IHC (LT)                          | Some samples also positive for LT transcripts and protein 140 of the examined women were HIV-positive. | (65, 98, 103, 155, 168); |
| Integumentary system                           |                             | 0.000054-0.00024  | qPCR (LT, VP1), qRT-PCR (LT), NGS, IHC (LT)                          | Some samples also positive for LT transcripts and protein 140 of the examined women were HIV-positive. | (65, 98, 103, 155, 168); |
| Actinic keratosis (101)                         |                             | 0.000054-0.00024  | qPCR (LT, VP1), qRT-PCR (LT), NGS, IHC (LT)                          | Some samples also positive for LT transcripts and protein 140 of the examined women were HIV-positive. | (65, 98, 103, 155, 168); |
| Atypical fibroxanthoma (37)                    |                             | 0.000054-0.00024  | qPCR (LT, VP1), qRT-PCR (LT), NGS, IHC (LT)                          | Some samples also positive for LT transcripts and protein 140 of the examined women were HIV-positive. | (65, 98, 103, 155, 168); |
| BCC (451)                                      |                             | 0.000054-0.00024  | qPCR (LT, VP1), qRT-PCR (LT), NGS, IHC (LT)                          | Some samples also positive for LT transcripts and protein 140 of the examined women were HIV-positive. | (65, 98, 103, 155, 168); |

© 2020 The Authors. APMIS Published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Medical Microbiology and Pathology
| Tissue (n)                               | Prevalence (average%; range) | Viral load | Method                                      | Comments                                                                 | Reference |
|-----------------------------------------|------------------------------|------------|---------------------------------------------|--------------------------------------------------------------------------|-----------|
| Mixed MCC-BCC (1)                       | 1 (100)                      | PCR (LT, sT, VP1), qPCR (LT), IHC (LT)      | Both tumors had a different, but truncated LT mutation.                  | (183)     |
| Bowen’s disease (110)                   | 17 (15.5; 0–69.2)            | PCR (LT, VP1), nPCR (LT, sT, VP1), qPCR (LT, VP1) | (41, 50, 175–177)                                                        |           |
| Dermato fibrosarcoma (1)                | 1 (100)                      | nPCR (LT)                                        |                                                                           | (50)      |
| Kaposi’s sarcoma (39)                   | 11 (28.2; 0–66.7)            | 0.00001–0.00685                                  |                                                                           | (13, 52, 53, 122, 184)                                     |
| Keratoacanthoma (215)                   | 25 (11.6; 0–100)             | 0.0001–0.10                                     | IHC (LT) was negative.                                                  | (43, 48, 50, 51, 175, 176, 185)    |
| Langerhans cell sarcoma (7)             | 3 (42.9)                     | qPCR (LT)                                        | All samples were negative for IHC (LT).                                 | (55)      |
| Melanoma (189)                          | 9 (4.8; 0–191.1)             | 0.0016–0.082                                    | Included BCC, SCC, Bowen’s disease, and actinic keratosis. Sixteen of the patients were bone marrow transplant patients (8) or CLL patients (8). Of these, the skin tumor of one bone marrow transplant was MCPyV positive. | (47, 49, 56, 57, 91, 122, 162, 177, 182) |
| Non-melanoma skin cancers (99)          | 31 (31.3; 6.3–36.1)          | PCR (LT), nPCR (LT)                             |                                                                           | (186, 187) |
| Porocarcinoma (67)                      | 45 (67.2; 0–100)             | 0.0022–0.212                                    |                                                                           | (45, 48, 50, 54, 188)          |
| SCC (877)                               | 24.9 (0–75)                  | 0.00013–0.316                                   | All IHC(LT) were negative; sequencing of some LT revealed.              | (36, 41–43, 45–50, 57, 122, 162, 175, 176, 180, 189–191) |
| SCC + BCC (10)                          | 4 (40)                       | PCR (LT) and qPCR (LT)                          | Not specified how many BCC and how many SCC samples were positive.       | (192)     |
| Combined SCC and neuroendocrine carcinoma (7) | 0 (0)                                      | IHC (LT)                                      |                                                                           | (155)     |
| Fanconi anemia-associated head and neck SCC (43) | 17 (39.5; 10.3–100)                        | qPCR (LT); IHC (LT, sT)                        | 3/29 samples positive by IHC (LT) 1/14 additional samples positive by qPCR.   | (193)     |
| Mixed MCC-SCC (21)                      | 2 (9.5; 0–100)               | PCR (LT, VP1), qPCR (LT), IHC (LT)             | One of the three patients with MCPyV seborrheic keratosis was immunosuppressed. | (59, 98, 162) |
| Seborrheic keratosis (20)               | 3 (15; 0–33.3)               | PCR (LT, VP1), PCR (LT, sT), Southern nPCR (LT, sT) |                                                                           | (91, 176, 177)                  |
| Trichoblastoma (41)                     | 11 (26.8)                    | PCR (LT, VP1)                                   |                                                                           | (181)     |
| Circulatory system                      |                              |                                                     |                                                                           |           |
| ALL (50)                                |                              | qPCR (LT, VP1), qPCR (LT, sT, VP1), NGS, IHC (LT) |                                                                           | (99)      |
| AML (29)                                |                              | qPCR (LT, VP1), qPCR (LT, sT, VP1), NGS, IHC (LT) |                                                                           | (81, 82, 194)               |
| CBCL (180)                              |                              | PCR (LT, sT), Southern blot, qPCR (LT, VP2), IHC (LT) | IHC (LT) was negative for all samples.                                  | (21, 92, 95)           |
PCR and droplet digital PCR, with the prevalence of 2.6% and a low viral load of 1–5 copies/μL (39). The presence of MCPyV VP1 transcripts was also detected in the urine of both immunosuppressed and non-immunosuppressed individuals (40). This draws a picture that MCPyV could potentially be transferred to many tissues through bodily fluids. Yet, it is clear that because the viral load in these compartments is low, the virus is most likely just passively being transferred and actively replicating not in blood cells the bloodstream nor in epithelial cells in urine.

MCPyV IN NON-MCC TUMORS

Considering the role of MCPyV in the development of MCC and the widespread prevalence of the virus across the body prompted researchers to investigate a possible role and presence of MCPyV in non-MCC cancers. Malignant tissues have been examined for the presence of viral DNA, transcripts, and proteins, with the results of these studies summarized in Table 1. A more detailed overview is given in Table S1. In most of the non-MCC tumors investigated, MCPyV DNA was detected by PCR. However, in those cases in which the copy number of the viral genome per cell was determined, MCPyV copies were shown to be very low with <<1 copy/cell, that is, several logs lower compared to virus-positive MCPyV tumor cells. In those cases, in which the expression of LT was monitored by immunohistochemistry, LT could only be detected in a handful of cases, even though the viral DNA was present.

The earliest observation associating MCPyV with non-MCC was the detection of MCPyV DNA in non-melanoma cancers of the skin from immunosuppressed patients (41). MCPyV was eventually detected in many other neoplasia in non-immunosuppressed individuals as well (listed in detail in Table 1 and Table S1). Among the various body sites, the integumentary system is well represented as a site for MCPyV-positive non-MCC tumors. Many non-melanoma skin cancers, including squamous cell carcinomas (41–47) and basal cell carcinomas (41, 48–50), are frequently found to contain MCPyV DNA or transcripts at a varying level. The presence of the virus was also detected in a few cases of keratoacanthoma (43, 48, 51), Kaposi’s

Table 1. (continued)

| Tissue (n) | Prevalence (average%; range) | Viral load1 | Method | Comments | Reference |
|-----------|-----------------------------|------------|--------|----------|-----------|
| CLL/SLL (378) | 54 (14.3; 0–66.7) | 0.000017–0.002 | PCR (LT, sT, VP1), qPCR (LT, sT, VP1, VP2), FISH (LT), IHC (LT) | Six had truncated LT (Two of them also full-length LT). | (21, 83–87, 96, 194, 195) |
| CTCL (352) | 13.9 (2.7; 0–88.9) | 0.0012–12.467 | PCR (LT, sT), Southern blot, qPCR (LT, VP2), IHC (LT, VP1) | Two MCPyV DNA-positive samples examined by IHC (LT) were negative for LT. No truncated LT in those samples that were sequenced. 4/4 were positive for IHC (LT) and IHC (VP1). Two other studies: All examined samples were negative for IHC (LT). | (21, 88–90, 92–95, 122, 177, 184) |
| Lymph nodes CLL/SLL patients (18) | 6 (33.3) | <0.0004 | PCR (LT, VP1), qPCR (sT) | Eleven were AIDS patients. | (97) |
| CML (6) | 0 (0) | qPCR (LT) | | | |
| Follicular lymphoma (17) | 0 (0) | qPCR (LT) | | | |
| Lymphoma (196) | 13 (6.6) | 0.000016–0.0027 | qPCR (LT) | From AIDS patients. | (52) |
| Mantle cell lymphoma (1) | 0 (0) | FISH (LT) | | | |
| Non-Hodgkin’s lymphoma (10) | 1 (10) | qPCR (LT) | | | |
| Primary effusion lymphoma (4) | 0 (0) | qPCR (LT) | | | |
| Small-cell carcinoma lymph node (4) | 0 (0) | qPCR (VT) | | | |
| Soft tissue | 0 (0) | IHC (LT) | | | |
| Desmoplastic tumor (24) | 0 (0) | PCR (LT, VP1) | | | |

1Viral genome copies/cell; 2Southern blot of positive PCR products.
sarcoma (52, 53), porocarcinoma (45, 54), atypical fibroxanthoma (48), and langerhans cell sarcoma (55). On the contrary, melanomas are not associated at all with MCPyV (56–58), with the exception of one case in which MCPyV LT transcripts were detected in four acral lentiginous melanomas and in five nodular melanomas, whereas superficial spreading melanomas were virus-negative (49). The viral load of MCPyV was significantly higher in these skin-related samples compared to other virus-positive non-MCC cancers, but the expression of the viral LT was solely detected in only one case of a combined MCC–squamous cell carcinoma (59). The high viral load observed in skin-related non-MCC cancers might not be a surprising phenomenon as one would expect, in that such a close proximity to the original replication of the virus would render other cells of the skin susceptible to the presence of the virus. Still, the observed tissues are showing a picture, in which the virus is not actively participating in the maintenance of the cancerous growth, as its LT is not present in the tumors or expressed at undetectable levels using immunohistochemistry.

As previously mentioned, MCPyV can also replicate in cultures of lung fibroblasts (30). Therefore, it might not be unexpected to detect MCPyV in tumors of the respiratory system. The virus was detected in 10 cases of lung carcinomas (36), but the majority of the studies demonstrated a general lack of viral presence in these tumors (60–62). The situation is similar in combined small-cell lung carcinomas, in which only a few number of tumors were found to contain MCPyV DNA (63–65), though the large majority of analyzed samples were lacking any sign of the virus (66–68). However, neither of them showed a detectable level of LT protein expression. Non-small-cell lung carcinoma was associated with the presence of MCPyV more tightly (69–71), although none of the examined non-small-cell lung carcinoma samples showed any LT protein expression (72). One exception was the detection of truncated LT in two non-small-cell lung carcinoma (69). Intriguingly, in one of these two non-small-cell lung carcinomas, a sample displayed a peculiar duality by containing both episomal and integrated MCPyV DNA, and expressing both the full-length and truncated LT protein (69). Despite the fact that this latter case has only been detected in one sample, it highlights the possibility that the episomal viral genome could possibly be maintained separately in the cytoplasm despite the integration event to the genome, as similarly observed in a few MCCs (73, 74). It is worth mentioning that healthy lung tissues are relatively well studied in this respect (36, 52, 60, 61, 75), with MCPyV transcripts detected in a similar number of cases compared to lung carcinomas and small-cell lung carcinomas. Nevertheless, compared to skin-related non-MCC tissue, tumors of the circulatory system do not have a higher frequency of MCPyV transcript-positive tissues or a higher rate of genomic integration, while a full LT protein expression could be detected in some of the tumors. LT was also expressed in 30 non-small-cell lung carcinoma (76) and in another 14 samples (69). Since the MCPyV has been successfully propagated in vitro in a lung fibroblast cell line (30), it is tempting to hypothesize that this high number of LT expressing lung carcinoma cells are arising from the fact that the virus could potentially propagate in the vicinity of these cells. Therefore, it could potentially integrate to some of the lung-related cancer cells.

MCPyV prevalence is low in most of the lymphatic system cancers studied, with the exception of tonsillar squamous cell carcinoma (32%; n = 150) (77, 78) and thymoma (15.2%; n = 46) (69, 79, 80). The expression of the LT was only examined in thymomas and from the seven samples that were MCPyV DNA-positive, with three containing detectable LT protein levels (79). It is important to note that benign lymph nodes also contained the transcript of the MCPyV sT to a small extent (80) and that the genome copy number in all positive examined lymphatic system tumors ranged between 0.000004 and 0.0013 (77, 78).

MCPyV also exhibited a presence in tumors of the circulatory system, as many leukemia cells were found to harbor MCPyV sequences. One acute myeloid leukemia sample was positive for MCPyV DNA (81), in contrast to other observations in which no sign of the virus was observed (82). Chronic lymphocytic leukemia cell also contained MCPyV transcripts (83–86), whereas truncated LT mRNA was also detected in six samples, of which two also harbored full-length LT mRNA (84). Although when examined, all the chronic lymphocytic leukemia samples were negative for LT protein expression (21, 87). The presence of the truncated LT transcripts may be a sign of viral genomic integration. Even so, considering that some samples also contained full-length LT, it is plausible that in these tumors the virus was initially present in the cytoplasm for a longer period before integration, but later lost its ability to express its proteins. In the one case in which the viral load was determined, it was markedly low between 0.000017 and 0.0012 viral copies per cell (86). Cutaneous T-cell lymphoma (CTCL) is a special non-Hodgkin’s lymphoma, which is migrating to and resides in the skin. Therefore, it is potentially more exposed to MCPyV than other leukemia cells. The studies on the association between MCPyV and...
CTCL are seemingly antagonizing each other, since some are reporting no detectable levels of MCPyV in CTCL cells (88–90), while others described a certain level of MCPyV DNA and transcripts in CTCL (91, 92). Although where the CTCL containing skin lesions were examined together with neighboring non-lesional skin tissues, the viral prevalence was similar between the two (93, 94). However, it is important to note that one of these studies has detected the expression of the VP1 protein in four and the expression of LT protein in one CTCL-related samples, which were completely absent in the controls (93). Cutaneous B-cell lymphomas (CBCL) are skin-resident, generally slowly growing B-cell lymphomas. Considering the fact that these are also in close proximity to the viral replication sites at the skin, the potential contribution of the virus to the development of CBCL cannot be ruled out. Yet, the available studies were only able to detect the MCPyV in CBCLs with a relatively low prevalence, without viral protein expression (21, 92, 95), and with a low viral load, with the average viral copy per cell at 0.009 copy/cell (92). No presence of MCPyV was detected in the studies examining chronic myelomonocytic leukemia cells (82), mantle cell lymphoma cells (96), follicular lymphomas (97), primary effusion lymphomas (52), small-cell carcinomas of the lymph nodes (98), and acute lymphoblastic leukemia (99). LT transcripts were found in one study, analyzing a set of non-Hodgkin’s lymphomas (100).

The available reports regarding the presence of MCPyV DNA in reproductive system-related tumors are scarce, although some studies are displaying some level of occurrence of the virus in prostate cancer (36, 101), breast cancer (102), and cervical cancer (103). Surprisingly, in one case of testicular cancer, the viral load was relatively high at 0.934 copies per cell. Unfortunately, LT protein expression was not assessed in this case (36). On the other hand, MCPyV-positive prostate cancers exhibited a lower viral copy number at 0.002 copies per cell (36), with samples from cervical cancer containing an even lower level of viral copies between 0.00003055 and 0.0015 per tumor cell (103, 104). MCPyV viral transcripts were not detected in any examined ovarian cancer samples and in the cancers of the vulva (65, 105), and only a small set of breast cancer cells were shown to contain viral transcripts (65, 102). Despite the low viral genome copy number in cervical cancer (≤0.0015), LT transcripts and protein were detected in cervical cancers originating from HIV-positive women (104). It is possible that the expression of LT in these tumors will have originally resulted from an HIV-related immunosuppression.

Compared to the previous examples, some of the tumor samples originating from the digestive track are harboring the MCPyV sequences, with a slightly higher frequency as in the case of esophageal cancer (45.1%) (106), liver cancer (62%) (36), or salivary gland cancer (26.2%) (107). In contrast, the maximum of detected viral genome copies per cell was 0.33 in an exceptionally outstanding case of a small-cell carcinoma of the parotid (108), followed by 0.026 in a case of oral cavity tumors (100). In other cases, the viral genome copy number per cell was even lower, between 0.0000054 and 0.0063 (44, 106, 109, 110). However, only one tumor sample, a small-cell carcinoma of the parotid showed expression of LT protein (108). In this particular case, a LT truncating mutation was also found (108). There was a significant difference between squamous cell carcinomas of the oral cavity and other oral cavity tumors, since approximately 40% of the examined oral cavity squamous cell carcinomas were positive for viral transcripts (36), even though the presence of the virus was barely detectable in other oral tumors. Only sporadically were tumors of the larynx, and in one case in the tumors of the mandible, throat and tongue (110) and one tumor of the jaw (100) MCPyV DNA-positive, but it is important to note that healthy oral tissues contained MCPyV transcripts at a relatively higher frequency of approximately 17% (111). LT protein was not detected in either of them, and the copy number of the virus per cell was low (0.00024–0.026) (100). Many other examined digestive track-associated cancers, including stomach cancer (62, 65) and colorectal cancer (41, 62, 112, 113), showed a very low or no positivity toward viral transcripts. This pattern of occurrence might draw a picture, in which the virus is present in the proximal part of the digestive system at a low level (rather in a latent from), but not in other parts.

A low prevalence of MCPyV was detected in bladder (4%; n = 147) (36, 62, 65) and renal cancer (3.7%; n = 81) (36, 62) samples, with the viral load in the tumor cells relatively low compared to MCCs, between 0.001 and 0.004 copies per cell (36). Considering that none of these tumors had a detectable level of LT protein (62, 65), it is presumed that the virus does not play a causative role in these cancers. It has to be noted that the virus was observed in the urine of healthy patients (40), though until now it is not clear whether this represents a way the body clears out the virus or whether these viral particles are originating form a potential host cell in the excretory system. In either case, the tissues of the excretory system could be potentially exposed to a higher titer of viral
particles, which could be acquainted for the detected viral DNA in the bladder and renal cancer samples.

MCPyV has sporadically been identified in tumors originating from other organ systems. MCPyV can rarely be traced in tumors of the skeletal system, including Ewing sarcomas, chordomas, chondrosarcoma, and rhabdosarcomas (105, 114). A limited number of desmoplastic tumors are the only soft tissue-related tumors examined thus far and did not harbor MCPyV DNA (105). Studies focusing on tumors of the nervous system described a limited number of cases in which MCPyV transcripts were detectable in a few schwannomas, meningiomas, glioblastomas (115), and neurofibromas (100), whereas no relation to the virus was established in neuroblastomas (65, 105, 116). Neuroblastoma is a childhood cancer, with approximately 90% of the cases occurring in children less than 5 years old (117). At this early age, children may not yet have been infected with MCPyV because seroepidemiological studies demonstrated that <20% of children aged 0–5 years displayed antibodies to the virus. This may explain the lack of involvement of MCPyV in this malignancy. Nevertheless, even in the cases of viral presence in tumors of the CNS, the assessed number of viral copies in the host cell was markedly low between 0.0000007 and 0.05 (75, 115). These results are in accordance with the study describing the lack of MCPyV in healthy brain tissues (118). The detected virus-positive samples were correspondingly low in neuroendocrine carcinomas, from which none were shown to be positive for LT protein expression (65, 119). This is particularly interesting, considering the initially proposed interaction between neuroendocrine Merkel cells and the MCPyV.

In summary, MCPyV DNA can be detected in most of the tumor tissues that have been examined. However, the role of MCPyV in tumors other than MCC remains obscure for several reasons:

1. The viral genome copy number is very low.
2. LT transcripts and protein are seldomly detected.
3. Truncated LT and viral genome integration are hallmarks for MCPyV-positive MCCs, but these characteristics have not systematically been investigated in non-MCC tumors. Only a few cases reported an expression of truncated LT and/or integration of the viral genome.
4. Not all groups studying the same type of tumor could reproduce a similar level of prevalence, viral load, or LT antigen expression.
5. Healthy adjacent non-tumor tissue was seldom tested.
6. The prevalence in healthy tissue was in several cases comparable to malignant tissue.
7. Potential pitfalls and shortcomings of the studies. They will be discussed in the next paragraph.

The prevalence of MCPyV in a specific tumor sometimes varied from study to study. Several reasons can explain the discrepancies between different studies. The detection of MCPyV DNA on PCR-based methods can be affected by the primers that were used. Indeed, many studies applied the LT primers originally used by Feng et al. (13). These primers are superior to primers directed against VP1 (41, 42, 120, 121). The quality of the samples may also affect the outcome of the PCR reaction, as several studies have reported that MCPyV DNA detection in fresh-frozen tissues is more reliable compared with detection in FFPE samples (66, 73, 122). Other factors that may influence the geno-prevalence may be that the cohort that was examined (immunocompetent vs immunocompromised patients, smoking and drinking habits, age, gender, geographic differences, etc.). Furthermore, the number of specimens examined may give a wrong idea of the incidence of MCPyV in a specific tumor (e.g., case reports vs large cohorts examined).

Another flaw of PCR-based studies is that DNA is extracted from a tumor biopsy. The tumor is a heterogeneous population that contains among others the tumor cells, infiltrating immune cells, endothelial cells, and cancer-associated fibroblasts (CAFs) (123). Knowing that fibroblasts can support viral replication and may be genuine host cells for the virus (30) and that infiltrating monocytes are reservoirs for the virus (37), positive PCR products may derive from viral sequences in CAFs and/or monocytes. PCR-based methods are also prone to contamination. Because MCPyV is chronically shed from the skin (29), contamination during tumor sample taking or handling cannot be excluded.

Fluorescence in situ hybridization (FISH), coupled with DNA hybridization chain reaction (HCR DNA FISH), has been shown to provide a highly sensitive approach to detect the viral genome in MCPyV-infected dermal fibroblasts in cell culture (124). This method can theoretically be adapted to detect integrated viral DNA elements in order to monitor the presence and relative copy number of the virus in non-MCC tumors. Combined with immunofluorescence, HCR DNA FISH was also proven to be useful in the detection of MCPyV proteins in cultured dermal fibroblasts, simultaneously with viral DNA (124). This combination of methods might provide an alternative solution to help identify fibroblast cells in tissues samples together with viral DNA elements.
FUTURE DIRECTIONS

To unequivocally establish a role of MCPyV in malignancies, other than MCC, additional well-controlled investigations are required, and larger cohorts should be examined for the presence of viral proteins (LT and/or sT). Several studies in cell culture and in animal models indicate that MCPyV sT, rather than LT, may be the main oncogenic protein (125–133). Hence, it may also be important to monitor the expression of sT. The genome state of the virus should be determined (episomal or integrated). Integration of the viral genome may be a prerequisite for the neoplastic process. This event is fulfilled in virus-positive MCC, but may be characteristic for polyomavirus-induced cancers, because integration of the human polyomavirus BK (BKPyV) genome seems to be an essential step in BKPyV-associated cancers (134). The gene-encoding LT should be sequenced to determine whether full-length or truncated LT is expressed. In situ hybridization against viral DNA or RNA should be done to ensure that the viral sequences are detected in tumor cells and not in other cell types in the tumor microenvironment. Matching adjacent non-neoplastic specimens should be included, and the viral load (genome copies/cell) should be determined. Moreover, fresh-frozen samples are favored over paraffin-embedded tissues. PCR-based studies on DNA extracted from tumor tissue should include a reverse transcriptase PCR control with primers against transcripts not found in the tumor but are exclusively expressed in cells of the tumor microenvironment. Matching adjacent non-neoplastic specimens should be included, and the viral load (genome copies/cell) should be determined. Moreover, fresh-frozen samples are favored over paraffin-embedded tissues. PCR-based studies on DNA extracted from tumor tissue should include a reverse transcriptase PCR control with primers against transcripts not found in the tumor cells as well, which might contribute to the development of cancer in the long term. sT was also recently detected to induce genomic instability in its host genome by targeting the E3 ubiquitin ligase (131). Such features of the two viral antigens may contribute to the accumulation of mutations in the host genome and could subsequently pave the road to cancerous transformation, even in the absence of the initial causative factor. However, this hypothesis should be verified by experimental evidence by future studies.

Although MCPyV may not be the culprit, its gene products may enhance the expression of oncoproteins from another co-infecting oncovirus, which may be responsible for the tumor. As such, MCPyV can enhance the oncogenic potentials of the co-habitant virus. The co-presence of MCPyV and human papillomavirus and Epstein–Barr virus in tumors has been reported (78, 103, 141, 142). The high seroprevalence of MCPyV in the human population, the in vitro oncogenic potentials of LT and sT, and its causal role in MCC suggest that this virus may play a role in other human cancers, especially in individuals with a compromised immune system.

ABBREVIATIONS

AD: adenocarcinoma; ALL: acute lymphoblastic leukemia; AML: acute monocyctic leukemia; BCC: basal cell carcinoma; CBCL: cutaneous B-cell lymphoma; CLL: chronic lymphocytic leukemia; CML: chronic myelomonocytic leukemia; CTCL: cutaneous T-cell lymphoma; ddPCR: droplet digital; FISH: fluorescence in situ hybridization; IHC: immunohistochemistry; LT: large T antigen; PCR: polymerase chain reaction; NEC: neuroendocrine
REFERENCES

1. Moens U, Krumbholz A, Ehlers B, Zell R, Johne R, Calvignac-Spencer S, et al. Biology, evolution, and medical importance of polyomaviruses: An update. Infect Genet Evol 2017;54:18–38.

2. Moens U, Calvignac-Spencer S, Lauber C, Ramqvist T, Feltkamp MCW, Daugherty MD, et al. ICTV virus taxonomy: Polyomaviridae. J Gen Virol 2017;98:1159–60.

3. Buck CB, Van Doorslaer K, Peretti A, Geoghegan EM, Tisza MJ, An P, et al. The ancient evolutionary history of polyomaviruses. PLoS Pathog 2016;12:e1005574.

4. Gross L. A filterable agent, recovered from Ak leukemia extracts, causing salivary gland carcinomas in C3H mice. Proc Soc Exp Biol Med 1953;83:414–21.

5. Morgan GF, Ludwig Gross, Sarah Stewart, and the 1950s discoveries of Gross murine leukemia virus and polyoma virus. Stud Hist Philos Biol Biomed Sci 1950;48:200–9.

6. Decaprio JA, Garcea RL. A cornucopia of human polyomaviruses. Nat Rev Microbiol 2013;11:264–76.

7. Baez CF, Brandão Varella R, Villani S, Villani S, Delbue S. Human polyomaviruses: the battle of large and small tumor antigens. Virology (Auckland) 2017;8:1173122X1774485.

8. Topalis D, Andrei G, Snoeck R. The large tumor antigen: a “Swiss Army knife” protein possessing the functions required for the polyomavirus life cycle. Antiviral Res 2013;97:122–36.

9. Moens U, Van Gheldue M, Johansen M. Oncogenic potentials of the human polyomavirus tumor regulatory proteins. Cell Mol Life Sci 2007;64:1656–78.

10. Gioreup O, Chang Y. Update on human polyomaviruses and cancer. Adv Cancer Res 2010;106:1–51.

11. Cheng J, Decaprio JA, Fluck MM, Schaffhausen BS. Cellular transformation by simian virus 40 and murine polyoma virus T antigens. Semin Cancer Biol 2009;19:218–28.

12. Dela Cruz FN, Giannitti F, Li L, Woods LW, Del Valle L, Delwart E, et al. Novel polyomavirus associated with brain tumors in free-ranging raccoons, Western United States. Emerg Infect Dis 2013;19:77–84.

13. Fung H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;319:1096–100.

14. Becker JC, Stang A, DeCaprio JA, Cerroni L, Lobbé C, Veness M, et al. Merkel cell carcinoma. Nat Rev Dis Primers 2017;3:17077.

15. Arora R, Chang Y, Moore PS. MCV and Merkel cell carcinoma: a molecular success story. Curr Opin Virol 2012;2:489–98.

16. Chang Y, Moore PS. Merkel cell carcinoma: a virus-induced human cancer. Annu Rev Pathol Mech Dis 2012;7:123–44.

17. Rodig SJ, Cheng J, Wardzala J, DoRosario A, Scanlon JJ, Laga AC, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest 2012;122:4645–53.

18. Schrama D, Sarosi E, Adam C, Ritter C, Kaemmerer U, Klopack E, et al. Characterization of six Merkel cell polyomavirus-positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration. Int J Cancer 2019;145:1020–32.

19. Fischer N, Brandner J, Fuchs F, Moll I, Grundhoff A. Detection of Merkel cell polyomavirus (MCPyV) in Merkel cell carcinoma cell lines: Cell morphology and growth phenotype do not reflect presence of the virus. Int J Cancer 2010;126:2133–42.

20. Velásquez C, Amako Y, Harold A, Toptan T, Chang Y, Shuda M. Characterization of a Merkel cell polyomavirus-negative Merkel cell carcinoma cell line CVG-1. Front Microbiol 2018;9:713.

21. Shuda M, Arora R, Kwun HJ, Feng H, Sarid R, Fernández-Figueras M-T, et al. Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer 2009;125:1243–9.

22. Paulson KG, Park SY, Vandeven NA, Lachance K, Thomas H, Chapuis AG, et al. Merkel cell carcinoma: current US incidence and projected increases based on changing demographics. J Am Acad Dermatol 2018;78:457–63.e2.

23. Houben R, Shuda M, Weinkm R, Schrama D, Feng H, Chang Y, et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 2010;84:7064–72.

24. Kean JM, Rao S, Wang M, Garcea RL. Seroprevalence of human polyomaviruses. PLoS Pathog 2009;5:1e1000363.

25. Pastrana DV, Tolstov YL, Becker JC, Moore PS, Chang Y, Buck CB. Quantitation of human seroreponsiveness to Merkel cell polyomavirus. PLoS Pathog 2009;5:9:1e1000578.

26. Kamminga S, Van Der Meijden E, Feltkamp MCW, Zaatjer HL. Seroprevalence of fourteen human polyomaviruses determined in blood donors. PLoS ONE 2018;13:10:e0206273.

27. Viscidi RP, Rollison DE, Sondak VK, Silver B, Messina JL, Giuliano AR, et al. Age-specific seroprevalence of merkel cell polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol 2011;18:1737–43.

28. Tolstov YL, Pastrana DV, Fernández-Figueras M-T, et al. Merkel cell polyomavirus infection II. MCV is a common human infection that clinically sheds from human skin. Cell Host Microbe 2016;19:775–87.

29. Schrama D, Sarosi E, Adam C, Ritter C, Kaemmerer U, Klopack E, et al. Characterization of six Merkel cell polyomavirus-positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration. Int J Cancer 2019;145:1020–32.

30. Liu W, Yang R, Payne AS, Schowalter RM, Spurlock M, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest 2012;122:4645–53.

31. Schrama D, Sarosi E, Adam C, Ritter C, Kaemmerer U, Klopack E, et al. Characterization of six Merkel cell polyomavirus-positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration. Int J Cancer 2019;145:1020–32.
of Japanese patients with Merkel cell carcinoma. J Clin Virol 2016;82:101–7.
32. Hashida Y, Kamioka M, Tanaka M, Hosokawa S, Murakami M, Nakajima K, et al. Ecology of Merkel cell polyomavirus in healthy skin among individuals in an Asian Cohort. J Infect Dis 2016;213:1708–16.
33. Ma JE, Brewer JD. Merkel cell carcinoma in immunosuppressed patients. Cancers (Basel) 2014;6:1328–50.
34. Koljonen V, Kukko H, Pukkala E, Sankila R, Böhling T, Tukiainen E, et al. Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma. Br J Cancer 2009;101:1444–7.
35. Matsushita M, Kuwamoto S, Iwasaki T, Higaki-Mori H, Yashima S, Kato M, et al. Detection of Merkel cell polyomavirus in the human tissues from 41 Japanese autopsy cases using polymerase chain reaction. Intervirology 2013;56:1–5.
36. Loyo M, Guerrero-Preston R, Braitt M, Hoque MO, Chuang A, Kim MS, et al. Quantitative detection of Merkel cell virus in human tissues and possible mode of transmission. Int J Cancer 2010;126:2991–6.
37. Mertz KD, Junt T, Schmid M, Pfaltz M, Kempf W. Inflammatory monocytes are a reservoir for Merkel cell polyomavirus. J Invest Dermatol 2010;130:1146–51.
38. Pancaldi C, Corazzari V, Maniero S, Mazzoni E, Comar M, Martinu F, et al. Merkel cell polyomavirus DNA sequences are frequently detected in nonmelanoma skin cancers of immunosuppressed patients. Int J Cancer 2009;125:356–62.
39. Kassem A, Technau K, Kurz AK, Pantulu D, Husseiny MI, Anastasi B, Singer J, Lacey SF. Presence of human polyomaviruses in renal transplant recipients and healthy subjects. J Clin Virol 2010;49:137–40.
40. Husseiny MI, Anastasi B, Singer J, Lacey SF. A comparative study of Merkel cell, BK and JC polyomaviruses infections in renal transplant recipients and healthy subjects. J Clin Virol 2010;49:137–40.
41. Kassem A, Technau K, Kurz AK, Pantulu D, Lönning M, Kayser G, et al. Merkel cell polyomavirus sequences are frequently detected in nonmelanoma skin cancer of immunosuppressed patients. Int J Cancer 2009;125:356–62.
42. Dworkin AM, Tseng SY, Iwenofu OH, Chuang A, Kim MS, et al. Human polyomaviruses and polyomaviruses in Merkel cell carcinoma and Kaposi’s sarcoma. J Med Virol 2009;81:1951–8.
43. Du-Thanh A, Guillot B, Dereure O, Fouloungne V. Detection of Merkel cell and other human polyomaviruses DNA in lesional and nonlesional skin from patients with Kaposi sarcoma. Br J Dermatol 2015;173:1063–5.
44. Pan  C, Pierucci F, Sollai M, Arvia R, Massi D, Zakrzewska K. Detection of Merkel cell polyomavirus DNA sequences in Langerhans cell histiocytosis. Front Oncol 2017;7:294.
45. Mertz KD, Fronczek J, Hafner C, Sollai M, Arvia R, Massi D, Zakrzewsk K. Detection of Merkel cell polyomavirus DNA in formalin fixed paraffin embedded (FFPE) cutaneous biopsies. J Virol Methods 2017;246:15–20.
46. Wieland U, Scola N, Stolte B, Stücker M, Silling S, Kreuter A. No evidence for a causal role of Merkel cell polyomavirus in keratoacanthoma. J Am Acad Dermatol 2012;67:41–6.
47. Purdie KJ, Proby CM, Rizvi H, Grifﬁn H, Doorbar J, Sommerlad M, et al. The role of human polyomaviruses and polyomaviruses in BRAF-inhibitor induced cutaneous squamous cell carcinoma and benign squamoproliferative lesions. Front Microbiol 2018;9:1806.
48. Scol  N, Wieland U, Silling S, Altmeier P, Stücker M, Kreuter A. Prevalence of human polyomaviruses in common and rare types of non-Merkel cell carcinoma skin cancer. Br J Dermatol 2012;167:1315–20.
49. Imajoh M, Hashida Y, Nakajima H, Sano S, Dai-bata M. Prevalence and viral DNA loads of three novel human polyomaviruses in skin cancers from Japanese patients. J Dermatol 2013;40:657–60.
50. Bellott TR, Baez CF, Almeida SG, Venceslau MT, Zalis MG, Guimarães MA, et al. Molecular prevalence of Merkel cell polyomavirus in nonmelanoma skin cancer in a Brazilian population. Clin Exp Dermatol 2017;42:390–4.
51. Haeggblom L, Franzen J, Näsmann A. Human polyomavirus DNA detection in keratoacanthoma and Spitz naevus: no evidence for a causal role. J Clin Pathol 2017;70:451–3.
52. Katano H, Ito H, Suzuki Y, Nakamura T, Sato Y, Tsuji T, et al. Detection of Merkel cell polyomavirus in Merkel cell carcinoma and Kaposi’s sarcoma. J Med Virol 2009;81:1951–8.
53. Murakami I, Kamioka M, Nemoto Y, et al. Merkel cell polyomavirus in keratoacanthoma. J Am Acad Dermatol 2017;76:281–4.
54. Du-Thanh A, Guillot B, Dereure O, Fouloungne V. Detection of Merkel cell and other human polyomaviruses DNA in lesional and nonlesional skin from patients with Kaposi sarcoma. Br J Dermatol 2015;173:1063–5.
55. Murakami I, Matsushita M, Iwasaki T, Kuwamoto S, Kato M, Horie Y, et al. High viral load of Merkel cell polyomavirus DNA sequences in Langerhans cell histiocytosis. J Clin Virol 2016;78:71–3.
56. Murakami M, Imajoh M, Ikawa T, Nakajima H, Kamioka M, Nemoto Y, et al. Presence of Merkel cell polyomavirus in Japanese cutaneous squamous cell carcinoma. J Clin Virol 2012;53:175–9.
57. Schmid M, Tronnier M, Kempf W. Detection of Merkel cell polyomavirus in keratoacanthoma. J Am Acad Dermatol 2012;67:41–6.
61. Shikova E, Emin D, Alexandrova D, Shindov M, Kumanova A, Lekov A, et al. Detection of Merkel cell polyomavirus in respiratory tract specimens. Intervirology 2017;60:28–32.
62. Toptan T, Yousem SA, Ho J, Matsushima Y, Stabile LP, Fernández-Figuera M-T, et al. Survey for human polyomaviruses in cancer. JCI insight 2016;1:e85562.
63. Andres C, Ihrler S, Puchta U, Flajg MJ. Merkel cell polyomavirus is prevalent in a subset of small cell lung cancer: a study of 31 patients. Thorax 2009;64:1007–8.
64. Helmbold P, Lahtz C, Herpel E, Schnabel PA, Dammann RH. Frequent hypermethylation of RASSF1A tumour suppressor gene promoter and presence of Merkel cell polyomavirus in small cell lung cancer. Eur J Cancer 2009;45:2207–11.
65. Jung HS, Choi Y-L, Choi J-S, Roh JH, Pyon JK, et al. Detection of Merkel cell polyomavirus in Merkel cell carcinosomas and small cell carcinomas by PCR and immunohistochemistry. Histol Histopathol 2011;26:1231–41.
66. Touze A, Gaitan J, Maruani A, Le Bidre E, Doussinaud A, Clavel C, et al. Merkel cell polyomavirus strains in patients with Merkel cell carcinoma. Emerg Infect Dis 2009;15:960–2.
67. Karimi S, Yousefi F, Seifi S, Khosravi A, Nadji SA. Identification of Merkel cell polyomavirus with a tumour-specific signature in non-small cell lung cancer. Br J Cancer 2010;103:439–42.
68. Wetzels CTAH, Hoefnagel JGM, Bakkers JMJE, Karimi S, Yousefi F, Seifi S, Khosravi A, Nadji SA. No evidence for a role of Merkel cell polyomavirus in small cell lung cancer among Iranian subjects. Pathol Res Pract 2014;210:836–9.
69. Martel-Jantin C, Filippone C, Cassar O, Peter M, Comar M, Cuneo A, Maestri I, Melloni E, Pozzato MF, Abdul-Hamid MA, Losen M, et al. Lack of evidence for direct involvement of Merkel cell polyomavirus (MCPyV) in chronic lymphocytic leukemia. Genes & Cancer 2012;6:220–8.
70. Behdarvand A, Zamani MS, Sadeghi F, Yahyapour Y, Vaziri F, Jamnani FR, et al. Evaluation of Merkel cell polyomavirus in non-small cell lung cancer and adjacent normal cells. Microb Pathog 2017;108:21–6.
71. Kim GJ, Lee JH, Lee DH. Clinical and prognostic significance of Merkel cell polyomavirus in non-small cell lung cancer. Medicine (Baltimore) 2017;96(3):e5413.
72. Bittar HET, Pantanowitz L. Merkel cell polyomavirus is not detected in lung adenocarcinomas by immunohistochemistry. Appl Immunohistochem Mol Morphol 2016;24:427–30.
73. Martel-Jantin C, Filipponi C, Cassar O, Peter M, Tomasic G, Vielli P, et al. Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma. Virology 2012;426:134–42.
74. Laude H, Jonchère B, Maubec E, Carliotti A, Marinho E, Couturaud B, et al. Distinct Merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with Merkel cell carcinoma. PLoS Pathog 2010;6:93–4.
75. Mancuso G, Antonia J, Sirini C, Salvo M, Giacomoletti L, Olivero C, et al. Frequent detection of Merkel cell polyomavirus DNA in tissues from 10 consecutive autopsies. J Gen Virol 2017;98:1372–6.
76. Xu S, Jiang J, Yu X, Sheng D, Zhu T, Jin M. Association of Merkel cell polyomavirus infection with EGFR mutation status in Chinese non-small cell lung cancer patients. Lung Cancer 2014;83:341–6.
77. Saláková M, Košlabová E, Vojtechova Z, Tachezy R, Sroller V. Detection of human polyomaviruses MCPyV, HPyV6, and HPyV7 in malignant and non-malignant tonsillar tissues. J Med Virol 2016;88:695–702.
78. Herberhold S, Hellmich M, Panning M, Bartok E, Silling S, Akgül B, et al. Human polyomavirus and human papillomavirus prevalence and viral load in non-malignant tonsillar tissue and tonsillar carcinoma. Med Microbiol Immunol 2017;206:93–103.
79. Chitineberg E, Kluftah F, Renisspiess D, Mannheims AB, Abdull-Hamid MA, Losen M, et al. Low prevalence of Merkel cell polyomavirus in human epithelial thymic tumors. Thorac Cancer 2019;10:445–51.
80. Toracchio S, Foyle A, Sroller V, Reed JA, Wu J, Kozinetz CA, et al. Lymphotropism of Merkel cell polyomavirus infection, Nova Scotia, Canada. Emerg Infect Dis 2010;16:1702–9.
81. Song Y, Gyarmati P. Identification of Merkel cell polyomavirus from a patient with acute myeloid leukemia. Genome Announc 2017;5:e01241-16.
82. Hashida Y, Imajoh M, Taniguchi A, Kamioka M, Daibata M. Absence of Merkel cell polyomavirus in monocytic leukemias. Acta Haematol 2013;130:135–7.
83. Trizuljak J, Srovnal J, Plevová K, Breychtová Y, Semerád L, Bakešová D, et al. Analysis of prognostic significance of Merkel cell polyomavirus in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2015;15:439–42.
84. Deepa Pantulu N, Pallasch CP, Kurz AK, Kassem A, Frenzel L, Sodenkamp S, et al. Detection of a novel truncating Merkel cell polyomavirus large T antigen deletion in chronic lymphocytic leukemia cells. Blood 2010;116:5280–4.
85. Comar M, Cuneo A, Maueri I, Melloni E, Pozzato G, Soffritti O, et al. Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease. J Clin Virol 2012;55:367–9.
86. Imajoh M, Hashida Y, Taniguchi A, Kamioka M, Daibata M. Novel human polyomaviruses, Merkel cell polyomavirus (MCPyV) and human papillomavirus prevalence and viral load in non-malignant tonsillar tissue and tonsillar carcinoma. J Oral Pathol Med 2012;41:162–9.
87. Comari L, Chtatinberg E, Klufah F, Rennspiess D, Mannheims AB, Abdull-Hamid MA, Losen M, et al. Lack of evidence for direct involvement of Merkel cell polyomavirus (MCPyV) in chronic lymphocytic leukemia. Med Microbiol Immunol 2017;206:93–103.
88. Herberhold S, Hellmich M, Panning M, Bartok E, Silling S, Akgül B, et al. Human polyomavirus and human papillomavirus prevalence and viral load in non-malignant tonsillar tissue and tonsillar carcinoma. Med Microbiol Immunol 2017;206:93–103.
89. Chitineberg E, Kluftah F, Renisspiess D, Mannheims AB, Abdull-Hamid MA, Losen M, et al. Low prevalence of Merkel cell polyomavirus in human epithelial thymic tumors. Thorac Cancer 2019;10:445–51.
90. Mirvish ED, Pomerantz RG, Geskin LJ. Infectious agents in cutaneous T-cell lymphoma. J Am Acad Dermatol 2011;64:423–31.
MCPyV IN NON-MCC TUMORS

91. Andres C, Belloni B, Puchta U, Sander CA, Flaug MJ. Prevalence of MCPyV in Merkel cell carcinoma and non-MCC tumors. J Cutan Pathol 2010;37:28–34.

92. Kreuter A, Silling S, Dewan M, Stücker M, Wieland U. Evaluation of 4 recently discovered human polyomaviruses in primary cutaneous B-cell and T-cell lymphoma. Arch Dermatol 2011;147:1449–51.

93. Du-Thanh A, Dereure O, Guilloit B, Foulounge V. Merkel cell polyomavirus: its putative involvement in a particular subset of cutaneous lymphoma with possibly unfavorable outcome. J Clin Virol 2014;61:161–5.

94. Gormley RH, Kim EJ, Rook AH, Kovarik CL, Sun A, Rady P, et al. Merkel cell polyomavirus in low levels in folliculotopic mycosis fungoides represents a passenger, not a driver. Int J Dermatol 2015;54:e182–3.

95. Andres C, Puchta U, Sander CA, Ruzicka T, Flaug MJ. Prevalence of Merkel cell polyomavirus DNA in cutaneous lymphomas, pseudolymphomas, and inflammatory skin diseases. Am J Dermatopathol 2010;32:593–8.

96. Haugg AM, Speel EJM, Pantulu ND, Pallascio C, Kurz AK, Kvasnicka HM, et al. Fluorescence in situ hybridization confirms the presence of Merkel cell polyomavirus in chronic lymphocytic leukemia cells. Blood 2011;117:5776–7.

97. Teman CJ, Tripp SR, Perkins SL, Duncavage EJ. Merkel cell polyomavirus (MCPyV) in chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Res 2011;35:689–92.

98. Paik JY, Hall G, Clarkson A, Toon C, Colebatch A, et al. Immunohistochemistry for Merkel cell polyomavirus is highly specific but not sensitive for the diagnosis of Merkel cell carcinoma in the Australian population. Hum Pathol 2011;42:1385–90.

99. Gustafsson B, Honkaniemi E, Goh S, Giraud G, Forestier E, Von Dobeln U, et al. KI, WU, and Merkel cell polyomavirus DNA was not detected in guthrie cards of children who later developed acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2012;34:364–7.

100. Tario S, Matsuhashi M, Kuwamoto S, Horie Y, Kodani I, Murakami I, et al. Low prevalence of Merkel cell polyomavirus with low viral loads in oral and maxillofacial tumours or tumour-like lesions from immunocompetent patients: absence of Merkel cell polyomavirus-associated neoplasms. Mol Clin Oncol 2015;3:1301–6.

101. Smelow V, Bzhalava D, Arroyo Mühr LS, Eklund C, Komyakov B, Gorelov A, et al. Detection of DNA viruses in prostate cancer. Sci Rep 2016;6:25235.

102. Peng J, Wang T, Zhu H, Guo J, Li K, Yao Q, et al. Multiplex PCR/mass spectrometry screening of biological carcinogenic agents in human mammary tumors. J Clin Virol 2014;61:255–9.

103. Salehi-Vaziri M, Sadeghi F, Alamsi-Hashiani A, Haeri H, Monavari SH, Keyvani H. Merkel cell polyomavirus and human papillomavirus infections in cervical disease in Iranian women. Arch Virol 2015;160:1181–7.

104. Imajoh M, Hashida Y, Nemoto Y, Oguri H, Maeda N, Furuhata M, et al. Detection of Merkel cell polyomavirus in cervical squamous cell carcinomas and adenocarcinomas from Japanese patients. Virol J 2012;9:154.

105. Sastre-Garau X, Peter M, Avril M-F, Laude H, Couturier J, Rozenberg F, et al. Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis. J Pathol 2009;218:48–56.

106. Yahyapour Y, Sadeghi F, Alizadeh A, Rajabnia R, Siadati S. Detection of Merkel cell polyomavirus and human papillomavirus in esophageal squamous cell carcinomas and non-cancerous esophageal samples in Northern Iran. Pathol Oncol Res 2016;22:667–72.

107. Chen AA, Gheit T, Stellin M, Lupato V, Spinato G, Fuson R, et al. Oncogenic DNA viruses found in salivary gland tumors. Oral Oncol 2017;75:106–10.

108. Fisher CA, Harms PW, McHugh JB, Edwards PC, Siddiqui J, Palanisamy N, et al. Small cell carcinoma in the parotid harboring Merkel cell polyomavirus. Oral Surg Oral Med Oral Pathol Oral Radiol 2014;118:703–12.

109. Yahyapour Y, Rahmani R, Alipour M, Alizadeh A, Khademian A, Sadeghi F. Prevalence and association of human papillomavirus, Epstein-Barr virus and Merkel Cell polyomavirus with neoplastic esophageal lesions in Northern Iran. Casp J Intern Med 2018;9:353–60.

110. Mohebbi E, Noormohamadi Z, Sadeghi-Rad H, Sadeghi F, Yahyapour Y, Yaziri F, et al. Low viral load of Merkel cell polyomavirus in Iranian patients with head and neck squamous cell carcinoma: Is it clinically important? J Med Virol 2018;90:344–50.

111. Baef C, Guimaraes MAAM, Martins RAG, Zalona ACJ, Cossatis JJ, Zalis MG, et al. Detection of Merkel cell polyomavirus in oral samples of renal transplant recipients without Merkel cell carcinoma. J Med Virol 2015;87:2016–9.

112. Campello C, Comar M, D’Agaro P, Minicoczi A, Rodella L, Poli A. A molecular case-control study of the Merkel cell polyomavirus in colon cancer. J Med Virol 2011;83:721–4.

113. Fiorina L, Ricotti M, Vanoli A, Luinetti O, Dullera E, Riboni R, et al. Systematic analysis of human oncogenic viruses in colon cancer revealed EBV latency in lymphoid infiltrates. Infect Agent Cancer 2014;9:18.

114. Yakkioui Y, Speel EJM, Van Overbeeke JJ, Boderic MJM, Pujari S, Hausen AZ, et al. Oncogenic viruses in skull base chordomas. World Neurosurg 2018;112:e7–13.

115. Sadeghi F, Salehi-Vaziri M, Alizadeh A, Ghodsi SM, Bokharaei-Salim F, Fateh A, et al. Detection of Merkel cell polyomavirus large T-antigen sequences in human central nervous system tumors. J Med Virol 2015:87:1241–7.

116. Giraud G, Ramqvist T, Pattrainer DV, Pavot V, Lindau C, Kogner P, et al. DNA from KI, WU and Merkel cell polyomaviruses in human central nervous system tumors or tumour-like lesions. J Med Virol 2015;87:1241–7.

117. Matthay KK, Maris JM, Schleiermacher G, Naka-gawaara A, Mackall CL, Diller L, et al. Neuroblastic neuroblastomas. PLoS ONE 2009;4:e8239.

118. Lam WY, Leung BW, Chu IMT, Chan ACL, Ng HK, Chan PKS. Survey for the presence of BK, JC, KI, WU and Merkel cell polyomaviruses in human brain tissues. J Clin Virol 2010;48:11–4.
119. Kervarrec T, Zaragoza J, Gaboriaud P, Le Gouge A, Beby-Defaux A, Le Corre Y, et al. Differentiating Merkel cell carcinoma of lymph nodes without a detectable primary skin tumor from other metastatic neuroendocrine carcinomas: The ELECTHPP criteria. J Am Acad Dermatol 2018;78:964–972.e3.

120. Kassem A, Schöpflin A, Diaz C, Weyers W, Stückeler E, Werner M, et al. Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res 2008;68:5009–13.

121. Nakajima H, Takaishi M, Yamamoto M, Kamijima R, Kodama H, Tarutani M, et al. Screening of the specific polyoma virus as diagnostic and prognostic tools for Merkel cell carcinoma. J Dermatol Sci 2009;56:211–3.

122. Foulongne V, Dereure O, Kluger N, Molot B, Segondy M. Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases. Br J Dermatol 2010;162:59–63.

123. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci 2012;125:5591–6.

124. Liu W, Krump NA, Buck CB, You J. Merkel cell polyomavirus infection and detection. J Vis Exp 2019, https://doi.org/10.3791/58950

125. Shuda M, Kwun HJ, Feng H, Chang Y, Moore PS. Human Merkel cell polyomavirus small T antigen is oncogenic in a DNA vaccine targeting the 4E-BP1 translation regulator. J Clin Invest 2011;121:3623–34.

126. Gomez B, He L, Tsai YC, Wu TC, Viscidi RP, Hung CF. Creation of a Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Virol 2007;81:1674–80.

127. Verhalen B, Starrett GJ, Harris RS, Jiang M. Functional upregulation of the DNA cytosine deaminase APOBEC3B by polyomaviruses. J Virol 2016;90:6379–86.

128. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013;45:977–83.

129. Vieira VC, Leonard B, White EA, Starrett GJ, Temiz NA, Lorenz LD, et al. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio 2014;5:e00234–14.

130. Mbisa JL, Barr R, Thomas JA, Vandezagraaf N, Doerweiler SJ, Svarovskaia ES, et al. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol 2007;81:7099–110.

131. Dillon-White M, Simon V. Contribution of APOBEC3-driven mutagenesis to HIV evolution and HIV drug resistance. In: Gotte M, Berghuis A, Matlashewski G, Wainberg M, Sheppard D, editors. Handbook of Antimicrobial Resistance. New York, NY: Springer, 2017:41–57.

132. Vazquez-Guillen JM, Palacios-Saucedo GC, Rivero-Morales LG, Alonzo-Morado MV, Burciaga-Bernal SB, Montufar-Martinez M, et al. Infection and coinfection by human papillomavirus, Epstein-Barr virus and Merkel cell polyomavirus in patients with squamous cell carcinoma of the larynx: A retrospective study. PeerJ 2018;10:e5834.

133. Moens U, Van Ghelue M, Eilers B. Are human polyomaviruses co-factors for cancers induced by other oncoviruses? Rev Med Virol 2014;24:343–60.

134. Kantola K, Sadeghi M, Lahtinen A, Koskenvuo M, Aaltonen LM, Mottonen M, et al. Merkel cell polyomavirus DNA in tumor-free tonsillar tissues and Epstein-Barr virus and Merkel cell polyomavirus in patients with squamous cell carcinoma of the larynx: A multiplex detection study. PeerJ 2018;10:e5834.

135. Aaltonen LM, Mattila A, Lehtinen K, Kullenberg M, et al. Human papillomavirus–specific polyoma virus as diagnostic and prognostic tools for Merkel cell carcinoma of the larynx: A retrospective study. J Clin Invest 2011;121:3623–34.

136. Kantola K, Sadeghi M, Lahtinen A, Koskenvuo M, Aaltonen LM, Mottonen M, et al. Merkel cell polyomavirus DNA in tumor-free tonsillar tissues and Epstein-Barr virus and Merkel cell polyomavirus in patients with squamous cell carcinoma of the larynx: A multiplex detection study. PeerJ 2018;10:e5834.

137. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013;45:977–83.

138. Vieira VC, Leonard B, White EA, Starrett GJ, Temiz NA, Lorenz LD, et al. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio 2014;5:e00234–14.

139. Mbisa JL, Barr R, Thomas JA, Vandezagraaf N, Doerweiler SJ, Svarovskaia ES, et al. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol 2007;81:7099–110.

140. Dillon-White M, Simon V. Contribution of APOBEC3-driven mutagenesis to HIV evolution and HIV drug resistance. In: Gotte M, Berghuis A, Matlashewski G, Wainberg M, Sheppard D, editors. Handbook of Antimicrobial Resistance. New York, NY: Springer, 2017:41–57.

141. Vazquez-Guillen JM, Palacios-Saucedo GC, Rivero-Morales LG, Alonzo-Morado MV, Burciaga-Bernal SB, Montufar-Martinez M, et al. Infection and coinfection by human papillomavirus, Epstein-Barr virus and Merkel cell polyomavirus in patients with squamous cell carcinoma of the larynx: A retrospective study. PeerJ 2018;10:e5834.

142. Moens U, Van Ghelue M, Eilers B. Are human polyomaviruses co-factors for cancers induced by other oncoviruses? Rev Med Virol 2014;24:343–60.

143. Kantola K, Sadeghi M, Lahtinen A, Koskenvuo M, Aaltonen LM, Mottonen M, et al. Merkel cell polyomavirus DNA in tumor-free tonsillar tissues and upper respiratory tract samples: implications for respiratory transmission and latency. J Clin Virol 2009;45:292–5.

144. Sadeghi M, Wang Y, Ramqvist T, Aaltonen LM, Pyöräi L, Toppinen M, et al. Multiplex detection in tonsillar tissue of all known human polyomaviruses. BMC Infect Dis 2017;17:409.

145. Cason C, Monasta L, Zanotta N, Campisciano G, Maestri I, Tommasino M, et al. Antibody response to polyomaviruses primary infection: high seroprevalence of Merkel cell polyomavirus and lymphoid tissue involvement. J Neurovirol 2018;24:314–22.

146. Schmitt M, Höfler D, Koleganova N, Pawlita M. Human polyomaviruses and other human viruses in
neuroendocrine tumors. Cancer Epidemiol Biomarkers Prev 2011;20:1558–61.

147. Dang X, Bialasiewicz S, Nissen MD, Sloots TP, Korálník JI, Tan CS. Infrequent detection of KI, WU and MC polyomaviruses in immunosuppressed individuals with or without progressive multifocal leukoencephalopathy. PLoS ONE 2011;6:e16736.

148. Hashida Y, Taniguchi A, Kawana S, Ushio Y, et al. Presence of Merkel cell polyomavirus DNA sequences in peripheral blood and tissues from patients with Langerhans cell histiocytosis. Hum Pathol 2014;45:119–26.

150. Lewis JS, Duncavage E, Klonowski PW. Oral cavity neuroendocrine carcinoma: a comparison study with cutaneous Merkel cell carcinoma and other mucosal head and neck neuroendocrine carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:209–17.

155. Duncavage EJ, Le BM, Wang D, Pfeifer JD. Merkel cell polyomavirus and extrapulmonary small cell carcinoma. Oncol Lett 2013;6:1049–52.

157. Stebbing J, Wickenden C, Castellano L, Sita-Lumsden A, Nelson M, Jacob J, et al. No evidence for a polyomavirus association or aetiology in AIDS-associated non-small cell lung cancer. AIDS 2010;24:1221–3.

158. Gheit T, Muñoz JP, Levican J, González C, Ampuero S, Parra B, et al. Merkel cell polyomavirus in non-small cell lung carcinomas from Chile. Exp Mol Pathol 2012;93:162–7.

160. Hashida Y, Imajoh M, Kamioka M, Taniguchi A, Kuroda N, Hayashi K, et al. Phylogenetic analysis of Merkel cell polyomavirus based on full-length LT and VP1 gene sequences derived from neoplastic tumours in Japanese patients. J Gen Virol 2014;95:135–41.

161. Lasithiotaki I, Tsitoura E, Koutoupolous A, Lagoudaki E, Koutoulaki C, Pittisianakis G, et al. A aberrant expression of miR-21, miR-376c and miR-145 and their target host genes in Merkel cell polyomavirus-positive non-small cell lung cancer. Oncotarget 2017;8:12371–83.

162. Kuwamoto S, Higaki H, Kanai K, Iwasaki T, Sano H, Nagata K, et al. Association of Merkel cell polyomavirus infection with morphologic differences in Merkel cell carcinoma. Hum Pathol 2011;42:632–40.

163. Hamister M, Asarkar A, Rogers D, Moore-Medlin T, McClure G, Ma X, et al. A pilot study of Merkel cell polyomavirus in squamous cell carcinoma of the tongue. Oral Oncol 2017;74:111–4.

164. Dickinson A, Xu M, Sileñ S, Wang Y, Fu Y, Sadeghi M, et al. Newly detected DNA viruses in juvenile nasopharyngeal angiofibroma (JNA) and oral and oropharyngeal squamous cell carcinoma (OSCC/OPSCC). Eur Arch Oto-Rhino-Laryngol 2019;276:613–7.

165. Cherneck RD, Duncavage EJ, Gnepp DR, El-Mofty SK, Lewis JS. Absence of merkel cell polyomavirus in primary parotid high-grade neuroendocrine carcinomas regardless of cytokeratin 20 immunophenotype. Am J Surg Pathol 2011;35:1806–11.

166. Wieland U, Mauch C, Kreuter A, Krieg T, Pfister H. Merkel cell polyomavirus DNA in persons without merkel cell carcinoma. Emerg Infect Dis 2009;15:1496–8.

168. Kolia-Diafouka P, Foulongne V, Boulle N, Ngou J, Koralnik IJ, Tan CS. Infrequent detection of KI, WU and MC polyomaviruses in immunosuppressed individuals with or without progressive multifocal leukoencephalopathy. PLoS ONE 2011;6:e39842.

169. Harkness R, Kelly PJ, McCluggage WG. Primary ovarian high-grade neuroendocrine carcinoma with Merkel cell-like immunophenotype arising in a teratoma. Int J Gynecol Pathol 2019. [Epub ahead of print]. https://doi.org/10.1097/PGP.0000000000000641.
tumors from Algeria compared with other types of breast cancer tumors. PLoS ONE 2014;9:e114559.

173. Fimereli D, Gacquer D, Fumagalli D, Salgado R, Rothi F, Larsimont D, et al. No significant viral transcription detected in whole breast cancer transriptomes. BMC Cancer 2015;15:147.

174. Reza MA, Reza MH, Mahdiedy L, Mehdi F, Nejad Hamid Z. Evaluation frequency of merkel cell polonyavirus, epithae-barr and mouse mammary tumor viruses in patients with breast cancer in kerman, southeast of Iran. Asian Pacific J Cancer Prev 2015;16:7351–7.

175. Ridd K, Yu S, Bastian BC. The presence of polyomavirus in non-melanoma skin cancer in organ transplant recipients is rare. J Invest Dermatol 2009;129:250–2.

176. Mertz KD, Pfaltz M, Juni T, Schmid M, Fernandez Figueras MT, Pfaltz K, et al. Merkel cell polyomavirus is present in common warts and carcinoma in situ of the skin. Hum Pathol 2010;41:1369–79.

177. Ota S, Ishikawa S, Takazawa Y, Goto A, Fujii T, Ohashi K, et al. Quantitative analysis of viral load per haploid genome revealed the different biological features of merkel cell polyomavirus infection in skin tumor. PLoS ONE 2012;7:e39954.

178. Falchook GS, Rady P, Hymes S, Nguyen HP, Tyring SK, Prieto VG, et al. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol 2013;149:322–6.

179. Andres C, Puchta U, Flag MJ. Detection of merkel cell polyomavirus DNA in atypical fibroxanthoma in correlation to clinical features. Am J Dermatopathol 2010;32:799–803.

180. Mertz KD, Paasinen A, Arnold A, Baumann M, Offer N, Willi N, et al. Merkel cell polyomavirus large T antigen is detected in rare cases of nonmelanoma skin cancer. J Cutan Pathol 2013;40:543–9.

181. Kassem A, Pantulu D, Technau K, Kurz AK, Diaz-C, Horster S, et al. Merkel cell polyomavirus in naevoid basal cell carcinoma syndrome-associated basal cell carcinomas and sporadic trichoblastomas. J Dermatol Sci 2010;10:140–2.

182. Haizt KA, Rady PL, Nguyen HP, He Q, Prieto VG, Tyring SK, et al. Merkel cell polyomavirus DNA detection in a patient with Merkel cell carcinoma and multiple other skin cancers. Int J Dermatol 2012;51:442–4.

183. Iwasaki T, Kodama H, Matsushita M, Kuroda N, Yamashita Y, Murakami I, et al. Merkel cell polyomavirus infection in both components of a combined Merkel cell carcinoma and basal cell carcinoma with ductal differentiation; Each component had a similar but different novel Merkel cell polyomavirus large T antigen truncating mutation. Hum Pathol 2013;44:442–7.

184. Foulongne V, Kluger N, Dereure O, Mercier G, Moles J-P, Guilbot B, et al. Merkel cell polyomavirus in cutaneous swabs. Emerg Infect Dis 2010;16:685–7.

185. Kim DK. No association between merkel cell polyomavirus infection and keratoacanthoma in Korean patients. Asian Pacific J Cancer Prev 2019;20:1299–301.

186. Hampras SS, Locke FL, Chavez JC, Patel NS, Giuliani AR, Miller K, et al. Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. Leuk Lymphoma 2018;59:911–7.

187. Baer CF, Goncalves MTV, da Rocha WM, Magalhaes de Souza L, Savassi-Ribas F, de Oliveira Almeida NK, et al. Investigation of three oncogenic epitheliotropic viruses shows human papillomavirus in association with non-melanoma skin cancer. Eur J Clin Microbiol Infect Dis 2019;38:1129–33.

188. Aung PP, Rady PL, Nagarajan P, Ivan D, Tetzlaff MT, Curry JL, et al. Detection of merkel cell polyoma virus and beta human papillomavirus in multiple eccrine poromas in a patient with acute leukemia treated with stem cell transplant. Am J Dermatopathol 2017;39:489–91.

189. Kaidbuchi-Noda K, Yokota K, Matsumoto T, Sawada M, Sakakibara A, Kono M, et al. Detection of Merkel cell polyomavirus in cutaneous squamous cell carcinoma before occurrence of Merkel cell carcinoma. J Am Acad Dermatol 2011;65:e152–4.

190. Ganzenmueller T, Yukushko Y, Kluba J, Henke-Gendo C, Gutzmer R, Schulz TF. Next-generation sequencing fails to identify human virus sequences in cutaneous squamous cell carcinoma. Int J Cancer 2012;131:E1173–79.

191. Rollison DE, Giuliano AR, Messina JL, Fenske NA, Cherbelis BS, Sondak VK, et al. Case-control Study of merkel cell polyomavirus infection and cutaneous squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2012;21:74–81.

192. Neto CF, Oliveira WRP, Costa PVA, Cardoso MK, Barreto PG, Romano CM, et al. The first observation of the association of Merkel cell polyomavirus and Merkel cell carcinoma in Brazil. Int J Dermatol 2019;58:703–6.

193. Toptan T, Brusadelli MG, Turpin B, Witte DP, Surrallés J, Velleuer E, et al. Limited detection of human polyomaviruses in Fanconi anemia related squamous cell carcinoma. PLoS ONE 2018;13:e0209235.

194. Comar M, Zanotta N, Del Savio R, Vascotto F, Calabrese N, Zorat F, et al. No evidence of Polyomavirus and EBV infections in Italian patients with mixed cryoglobulinemia infected chronically with HCV. J Med Virol 2014;86:666–71.

195. Cimino PJ, Bahler DW, Duncavage EJ. Detection of Merkel cell polyomavirus in chronic lymphocytic leukemia T-cells. Exp Mol Pathol 2013;94:40–4.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Prevalence of MCPyV in non-MCC tumors and non-malignant matching tissue.